دورية أكاديمية
Nitrous Oxide in Treatment Resistant Major Depression: Should We Laugh About It?
| العنوان: | Nitrous Oxide in Treatment Resistant Major Depression: Should We Laugh About It? |
|---|---|
| المؤلفون: | B. Leal, D. Vila-Chã, S. Garcia, I. Pinto, R. Mateiro, M. Avelino, M. Martins, J. Salgado |
| المصدر: | European Psychiatry, Vol 65, Pp S716-S716 (2022) |
| بيانات النشر: | Cambridge University Press, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Psychiatry |
| مصطلحات موضوعية: | Depression, Treatment Resistant Major Depression, Nitrous Oxide, Psychiatry, RC435-571 |
| الوصف: | Introduction Nitrous oxide (NO), also known as “laughing gas” is a colorless gas used as an anesthetic, a propellant in some foods, an engine performance enhancer and a recreational drug. When inhaled, it is known to provoke a rapid feeling of euphoria or excitement for a short period of time, dissociative phenomena and sometimes laughter. As its fellow anesthetic agent and NMDA-receptor antagonist, ketamine, NO is being studied for its possible therapeutic profile in treatment resistant major depression (TRMD). Objectives TRMD is a serious illness, that urges for effective alternative treatments. In that regard, we explored the recent studies conducted in these patients, using NO in different dosages when compared to placebo. Methods The authors revised the published literature about this topic, selecting relevant articles with the topic words: “Depression”, “Treatment Resistant Major Depression” and “Nitrous Oxide” in scientific data base. Results Since 2018, at least two randomized clinical trials have demonstrated that NO has considerable antidepressant effects in TRMD, when compared to placebo. Investigators noted that these positive effects where maintained at least for two weeks after a single 1-hour inhalation. In a more recent study, scientists compared different NO concentrations (25% vs. 50%) concluding that the 25% concentration had similar efficacy with a lower risk of adverse effects. Conclusions There appears to be encouraging results when treating patients with TRMD with NO in a 25% concentration. Nonetheless, there is need for further investigation, namely through studies that compare NO with other valid TRMD treatments and not only versus placebo. Disclosure No significant relationships. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 0924-9338 1778-3585 |
| Relation: | https://www.cambridge.org/core/product/identifier/S0924933822018478/type/journal_article; https://doaj.org/toc/0924-9338; https://doaj.org/toc/1778-3585 |
| DOI: | 10.1192/j.eurpsy.2022.1847 |
| URL الوصول: | https://doaj.org/article/e77f2c389ca64f6d9493782cc305fb34 |
| رقم الأكسشن: | edsdoj.77f2c389ca64f6d9493782cc305fb34 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 09249338 17783585 |
|---|---|
| DOI: | 10.1192/j.eurpsy.2022.1847 |